Healing peptides and tissue repair
When you strain a tendon or overwork a muscle, your body runs a repair sequence: inflammation, new blood vessels, rebuilt tissue. So-called healing peptides like BPC-157 and TB-500 are studied for how they interact with that sequence.
Most of the research so far is preclinical — worth understanding before forming expectations — and these articles are honest about that line. They cover the mechanisms, the evidence, and the practical questions people ask, with every compound available only by prescription after a provider review.
56 articles on this topic
-
1984 Nobel Prize in Chemistry: Making Peptides
Bruce Merrifield’s bead method made peptides easier to build. The breakthrough explains modern synthesis—and why purity testing still matters.
-
FDA Peptide Policy: Under Review, Not in Effect Yet
The White House logged a new FDA peptide policy notice on October 14, 2026, but the text is not public yet. Here is what the official record confirms, what unnamed sources reported about BPC-157, and what stays the same today.
-
BPC-157 for Ligaments: Animal Evidence, Human Gaps
The ligament claim comes from a rat knee study. Human trials have not shown that BPC-157 repairs an ACL tear or shortens recovery from a sprain.
-
10 Questions to Ask Before BPC-157
Ten questions explain what a BPC-157 visit needs to cover, from medical history and evidence limits to sport testing and follow-up.
-
TB-500 Myths: Ten Claims Checked Against Studies
TB-500's benefits in humans have not been established. Ten common claims get graded against the actual molecule, study and outcome behind them.
-
TB-500 News Update: October 2026
A new rat study adds tendon data, while the human evidence gap remains. July's FDA review and September's sports list answer different questions.
-
Peptide Myths: 10 Common Claims Checked
Ten things people say about peptides online, from "they're steroids" to "drug tests can't find them," graded against the studies and the rules that can actually answer them.
-
Should I Take BPC-157? How a Provider Decides
Should I take BPC-157? It may be worth discussing for a specific, examined problem, but a provider first checks the injury, the gut, drug testing, cancer history, pregnancy and your other medicines.
-
TB-500 FDA Review: Where It Stands After the Vote
TB-500 has never had an FDA-approved product. Its review for a federal compounding list ran from a 2022 nomination to a July 2026 committee vote, and FDA has not acted on that vote yet.
-
Wolverine Peptide Study: Use Is Up, Proof Isn't
A September preprint read de-identified doctors' notes and found new BPC-157 users up 33-fold since 2020, increasingly male and younger. It shows who is using it and where they get it, not whether it works.
-
Who Discovered TB-500? The Full Story
The short answer starts with Teresa Low, Shu-Kuang Hu, and Allan Goldstein, who sequenced thymosin beta-4 in 1981. The seven-amino-acid fragment now called TB-500 came later, and the record does not name one inventor.
-
BPC-157 News Update: September 2026
A July FDA advisory vote moved the conversation forward, but it did not change the law or establish that BPC-157 works in people. A new rat study adds evidence, with the same important limit: it was not a human trial.
-
Hims Peptides: What Hims & Hers Plans to Sell
Hims & Hers says a peptide and wellness category is coming, but the rollout is phased. Some offerings are planned for 2026, while BPC-157 depends on unfinished FDA rulemaking.
-
BPC-157 and Alcohol: Can You Drink Safely?
No published human study has tested the combination. The alcohol claims come from experiments in mice and rats, which cannot establish a safe drinking amount or a hangover remedy.
-
Gray Market Peptides: What Johns Hopkins Found
Johns Hopkins says the market for unverified peptide vials is growing much faster than the human evidence. The useful question is what a prescription and a pharmacy change.
-
BPC-157 Myths: 10 Claims Checked
Ten familiar claims about BPC-157, graded against the studies: what comes from rats, what has been observed in people, and what remains unknown.
-
BPC-157 Human Studies: What the Evidence Shows
Human evidence exists, but it is much smaller than online summaries make it sound: a few short, uncontrolled reports cannot establish that BPC-157 works or is safe long term.
-
Who Discovered BPC-157? Predrag Sikirić
Predrag Sikirić's group at the University of Zagreb described the parent gastric peptide in 1992 and the 15-amino-acid fragment BPC-157 in 1993. The history is much clearer than the human evidence.
-
KLOW Peptide Before and After: An Honest Timeline
There is no clinical before-and-after timeline for KLOW because no published study has tested the finished blend. Here is what component studies measured over three days to 12 weeks—and why those clocks are not a promise.
-
TB-500 10 mg: What the Vial Size Really Means
A 10 mg mark states the total peptide mass the vial is meant to contain. It is not a per-injection dose, a concentration, or proof that an unverified vial contains what its label claims.
Page 1 of 3 · 56 articles